A phase I study investigated the maximum tolerated dose (MTD), safety, pharmacodynamics, immunological correlatives, and anti-tumor activity of CP-870,893, a CD40 agonist antibody, when administered in combination with gemcitabine in patients with advanced PDAC. This evidence concerns the gene CD40 and neoplasm.